Vaccine · 2017 · 27 citations · 25 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccine ImmunologyVaccinologyAdverse Events Following ImmunizationVaccinationVaccine EffectivenessVaccine EfficacyVaccine SafetyViral VaccinesEnzyme-linked Immunosorbent Assay (Elisa)Group Sequential TrialsHemagglutination AssaysHemagglutination Inhibition AssaysInjection SitesPlacebo-controlled Vaccine TrialsSeasonal Influenza VaccinationSeasonal Influenza Vaccines
OBJECTIVES: Randomized, blinded, placebo-controlled trial to evaluate the safety and immunogenicity of ZOSTAVAX™ (ZV) administered concomitantly with quadrivalent inactivated influenza vaccine (IIV4) in adults≥50years of age (NCT02519855). METHODS: Overall, 440 participants were randomized into the Concomitant Group (CG) and 442 into the Sequential Group (SG). The CG received ZV and IIV4 at separate injection sites on Day 1 and matching placebo at Week 4. The SG received placebo and IIV4 (2015-2016 influenza season) at separate injection sites on Day 1 and ZV at Week 4. IMMUNOGENICITY ENDPOINTS: Varicella-zoster virus (VZV) antibody geometric mean titer (GMT) and geometric mean fold-rise (GMFR) from baseline to 4weeks postvaccination, measured by glycoprotein enzyme-linked immunosorbent assay (gpELISA) and adjusted for age and prevaccination titer. Influenza strain-specific GMT at baseline and 4weeks postvaccination was measured by hemagglutination inhibition (HAI) assay. SAFETY ENDPOINTS: Injection-site and systemic adverse experiences (AEs) within 28days following any vaccination and serious AEs throughout the study. RESULTS: The adjusted VZV antibody GMT ratio (CG/SG) was 0.87 (95%CI: 0.80, 0.95), meeting the prespecified noninferiority criterion. The VZV antibody GMFR in the CG was 1.9 (95%CI: 1.76, 2.05), meeting the acceptability criterion. Influenza antibody GMT ratios for A/H1N1, A/H3N2, B/Yamagata and B/Victoria were 1.02 (95%CI: 0.88, 1.18), 1.10 (95%CI: 0.94, 1.29), 1.00 (95%CI: 0.88, 1.14), and 0.99 (95%CI: 0.87, 1.13), respectively. The frequency of vaccine-related injection-site and systemic AEs was comparable between groups. No vaccine-related serious AE was observed. CONCLUSION: The concomitant administration of ZV and IIV4 to adults≥50years of age induced VZV-specific and influenza-specific antibody responses that were comparable to those following administration of either vaccine alone, and was generally well tolerated.
25
Influenza-Associated Hospitalizations in the United States
W. Thompson · JAMA · 2004 · 2.2K citations
Veterinary Medicine, Infectious Diseases, Disease Surveillance +15
Comparative analysis of two rates
Olli S. Miettinen, Markku Nurminen · Statistics in Medicine · 1985 · 1.1K citations